Sign In
Buy SMMT
$15.07
+0.210 (+1.41%)
At Close: Jun 03, 2026
2 High-Potential Growth Stocks You Shouldn't Overlook
07:30am, Sunday, 29'th Sep 2024
Intuitive Machines secured a NASA contract worth up to $4.82 billion, positioning it as a leader in the emerging trillion-dollar space industry. Summit Therapeutics' ivonescimab outperformed the world
Better Rising Biotech: Viking Therapeutics vs. Summit Therapeutics
07:03am, Saturday, 28'th Sep 2024
Viking Therapeutics and Summit Therapeutics both have potential blockbusters on their hands. Their shares have soared this year on the back of strong clinical progress.
2 Stocks Up Over 700% in 2024 That Could Soar Even Further
04:56am, Wednesday, 25'th Sep 2024
Summit Therapeutics' stock is way up in response to clinical trial results that suggest the cancer therapy it's developing could become the standard of care for lots of patients. Instil Bio stock soar
This Stock Is Crushing Nvidia's Performance This Year: Is It Too Late to Buy?
04:15pm, Sunday, 22'nd Sep 2024
This biotech has skyrocketed in value since January. It owes its performance to a potential billion-dollar cancer drug.
Summit Therapeutics Bests Merck's Top Selling Drug In Phase III Trial
02:33pm, Thursday, 19'th Sep 2024
Summit Therapeutics' ivonescimab shows improved efficacy over Merck's Keytruda in Phase III trials, targeting both PD-1 and VEGF, potentially expanding the PD-1 inhibitor market. Despite risks, Summit
Is It Too Late to Buy Summit Therapeutics Stock After Its Almost 10X Gain This Year?
05:50am, Thursday, 19'th Sep 2024
Positive results for Summit's cancer drug in a head-to-head study against Keytruda have caused its stock to soar. Investors have great expectations for Summit's lead candidate.
This Company Generates No Revenue and Its Market Cap Is Over $20 Billion. Here's Why That Valuation May Not Be All That Ridiculous.
09:53am, Wednesday, 18'th Sep 2024
Summit's cancer drug ivonescimab outperformed Keytruda in a recent clinical trial. The success of that trial led to a massive rally for the healthcare stock.
Here's Why Everyone's Talking About Summit Therapeutics
04:24am, Tuesday, 17'th Sep 2024
A bispecific antibody Summit Therapeutics licensed from Akeso outperformed the world's best-selling cancer therapy. In a phase 3 trial, treatment with ivonescimab reduced patients' risk of disease pro
Trade It or Fade It: The week's big biotech moves
06:52pm, Friday, 13'th Sep 2024
Jared Holz, Mizuho, joins 'Fast Money' to talk his playbook on recent biotech movers.
Why Summit Therapeutics Skyrocketed 123% This Week
10:30am, Friday, 13'th Sep 2024
Summit's Ivonescimab bested Keytruda in a phase 3 trial for lung cancer patients with the PD-L1 gene. Following the early-week stock spike, Summit raised over $200 million from investors.
Why Summit Therapeutics Stock Is Soaring Again Today
11:53am, Thursday, 12'th Sep 2024
Several accredited investors entered an agreement to buy roughly $235 million of Summit Therapeutics stock. These investors included several of the biopharmaceutical company's executives and board mem
Summit Therapeutics Surges on Trial Results: Time to Buy?
09:17am, Thursday, 12'th Sep 2024
Summit Therapeutics Inc. NASDAQ: SMMT has seen a meteoric rise this month, surging over 106% after releasing positive clinical trial results for its experimental cancer therapy. Year-to-date, the stoc
Summit Therapeutics Co-CEOs on what's next for lung cancer drug
06:28pm, Wednesday, 11'th Sep 2024
Bob Duggan & Maky Zanganeh, Summit Therapeutics co-CEOs, join 'Fast Money' to talk its lung cancer drug and continuing treatment studies.
Summit Hits Record High on Lung Cancer Drug Topping Merck's Keytruda
01:20pm, Tuesday, 10'th Sep 2024
Data from a late-stage study shows that SMMT's experimental antibody beat Keytruda in a head-to-head setting in treating certain patients with NSCLC.
Is Summit Therapeutics a Buy Now?
04:27am, Tuesday, 10'th Sep 2024
Ivonescimab is a bispecific antibody that targets PD-1 and VEGF to treat lung cancer. In a phase 3 trial, patients treated with ivonescimab were 49% less likely to experience their disease worsening t
